The potential risk factors of placenta increta and the role of octamethylcyclotetrasiloxane
Autor: | Fangling Zeng, Weitao Ye, Yan Long, Hongling Yang, Shanshui Zeng, Fei Gao, Qiangsheng Gan, Mengru Han, Xianhui Dong, Min Jiang, Chunyan Zhu, Yanwei Hu |
---|---|
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Siloxanes Placenta accreta Placenta Placenta Previa Placenta Accreta Abortion Pregnancy Risk Factors medicine Humans Child Retrospective Studies Potential risk business.industry Obstetrics Cesarean Section Obstetrics and Gynecology Trophoblast General Medicine Trophoblast cell medicine.disease medicine.anatomical_structure Case-Control Studies Gestation Female business Placenta Increta After treatment |
Zdroj: | Archives of gynecology and obstetrics. 306(3) |
ISSN: | 1432-0711 |
Popis: | The study aimed to investigate the potential risk factors for the placenta accreta spectrum (PAS), determine the predictive value of a diagnostic model, and evaluate the effects of octamethylcyclotetrasiloxane (OMCTS) on trophoblast proliferation and migration. This case–control study included 244 pregnant women with PAS and 327 normal pregnant women who visited Guangzhou Women and Children’s Medical Centre, China, from January 2014 to December 2017. Blood was collected from 42 women with PAS and 77 controls, and plasma specimens were analyzed by gas chromatography–time-of-flight mass spectrometry. In addition, the proliferation and migration of trophoblast cells were examined after treatment with OMCTS. We found an association between the risk of PAS and clinical factors related to fasting blood glucose levels (BS0, OR = 5.78), as well as factors related to endometrial injury [history of cesarean section (OR = 179.59), uterine scarring (OR = 68.37), and history of abortion (OR = 5.66)]. Equally important, pregnant women with PAS had significantly higher plasma OMCTS concentrations than controls. In vitro, we found that OMCTS could promote the proliferation and migration of HTR8/SVneo cells. The model of combining clinical factors and OMCTS had a good performance in PAS prediction (AUC = 0.97, 95% CI 0.78–0.93). The early diagnosis of PAS in pregnant women requires assessing risk factors, metabolic status, and BS0 levels before 20 weeks of gestation. OMCTS may be related to the development of PAS by promoting trophoblast cell proliferation and migration. |
Databáze: | OpenAIRE |
Externí odkaz: |